- Home
- OBIO vs UIS Comparison
OBIO vs UIS Comparison
Compare OBIO & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- UIS
- Stock Information
- Founded
- OBIO 2017
- UIS 1942
- Country
- OBIO United States
- UIS United States
- Employees
- OBIO N/A
- UIS N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- UIS EDP Services
- Sector
- OBIO Health Care
- UIS Technology
- Exchange
- OBIO Nasdaq
- UIS Nasdaq
- Market Cap
- OBIO 205.0M
- UIS 474.3M
- IPO Year
- OBIO N/A
- UIS N/A
- Fundamental
- Price
- OBIO $5.83
- UIS $6.25
- Analyst Decision
- OBIO Strong Buy
- UIS
- Analyst Count
- OBIO 4
- UIS 0
- Target Price
- OBIO $15.75
- UIS N/A
- AVG Volume (30 Days)
- OBIO 44.2K
- UIS 471.1K
- Earning Date
- OBIO 11-11-2024
- UIS 10-29-2024
- Dividend Yield
- OBIO N/A
- UIS N/A
- EPS Growth
- OBIO N/A
- UIS N/A
- EPS
- OBIO N/A
- UIS N/A
- Revenue
- OBIO $2,079,000.00
- UIS $1,988,200,000.00
- Revenue This Year
- OBIO $7.68
- UIS $0.18
- Revenue Next Year
- OBIO $110.40
- UIS $3.27
- P/E Ratio
- OBIO N/A
- UIS N/A
- Revenue Growth
- OBIO N/A
- UIS N/A
- 52 Week Low
- OBIO $4.22
- UIS $2.60
- 52 Week High
- OBIO $11.69
- UIS $8.12
- Technical
- Relative Strength Index (RSI)
- OBIO 60.54
- UIS 53.20
- Support Level
- OBIO $5.20
- UIS $6.18
- Resistance Level
- OBIO $5.99
- UIS $7.20
- Average True Range (ATR)
- OBIO 0.38
- UIS 0.34
- MACD
- OBIO 0.12
- UIS 0.03
- Stochastic Oscillator
- OBIO 87.20
- UIS 45.86
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About UIS Unisys Corporation New
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.